OMEICOS Therapeutics GmbH - News

OMEICOS Announces Formation of Inaugural Clinical Advisory Board

Leading Experts in Atrial Fibrillation to Complement the Company’s Key Focus Area

Berlin, Germany, November 13, 2017 — OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of leading experts in the field of cardiac arrhythmias to the company’s Clinical Advisory Board (CAB). The multinational group of specialists will serve as a strategic resource to OMEICOS as it continues to advance its lead compound, OMT-28, currently in a Phase I clinical trial. The CAB will provide counsel to the company as OMEICOS starts to design a Phase II program for maintenance of sinus rhythm in patients with atrial fibrillation.

OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology

OMEICOS adds REMIGES Ventures as new investor and announces the incorporation of U.S. subsidiary OMEICOS Ophthalmics, Inc.

Berlin, Germany, and Boston, MA, USA, October 04, 2017 — OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced that it has secured an extension of its recently closed Series B financing round. The financing by US-based REMIGES Ventures will help to expand the development of OMEICOS’ technology into the field of ophthalmological disorders. The company’s novel technology is based on stable synthetic small molecules which mimic natural highly bioactive lipid mediators derived from omega-3 fatty acids. REMIGES Ventures joins the existing investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II GmbH & Co. KG (HTGF) and KfW Group. Financial details of the additional investment were not disclosed.

OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

Clinical Trial in Atrial Fibrillation Ongoing as OMEICOS Evaluates Therapeutic Paradigm in Additional Indication Areas

Berlin, Germany, June 07, 2017 — OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation, today announced the approval of a new grant by the German Ministry of Education and Research (BMBF). The grant of approximately €1.7 million covers half of the investment needed to advance an OMEICOS research project with the other half coming from the funds secured in a Series B round from an investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II GmbH & Co. KG (HTGF), KfW Group and The Falck Revocable Trust, Ascenion GmbH and members of the management team earlier this year. The project will facilitate further research activities into OMEICOS’ novel approach to treat cardiovascular diseases and to explore its potential in other areas of high unmet medical need. With this renewed support from the German government as part of the Ascenion Spinnovator program, OMEICOS has secured so far roughly €4 million non-dilutive funding.

OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial

Financing Provides Runway Beyond Completion of First-in-man Trial with Lead Compound OMT-28 for Treatment of Atrial Fibrillation

Berlin, Germany, March 1, 2017 -OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced the first closing of a Series B financing round of €8.3 million and the initiation of a Phase 1 clinical trial with lead compound OMT-28 for the treatment of atrial fibrillation. The financing was led by Vesalius Biocapital II S.A. SICAR and SMS Company Group, along with existing investors KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG (HTGF), The Falck Revocable Trust, Ascenion GmbH and members of the management team. The funding will be used to support the newly initiated clinical program and to further leverage the therapeutic potential of the technology.

OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation

Berlin, Germany, November 2, 2015 - OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation, today announced the approval of an approximately €1.7 million grant by the German Ministry of Education and Research (BMBF). The grant covers half of the investment needed to advance an OMEICOS’ research project with the other half coming from the funds secured in a Series A round from an investor consortium including Vesalius Biocaptial II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gruenderfonds II GmbH & Co. KG (HTGF) and KfW Group earlier this year. The project will facilitate further research activities into OMEICOS’ novel approach to treat atrial fibrillation using orally available small molecule drug candidates and to explore their potential in other areas of high unmet medical need.